Philip­pines sus­pends dengue vac­ci­na­tion pro­gramme

BioSpectrum (Asia) - - Regulatory News -

The Philip­pines depart­ment of health has halted the use of Dengvaxia. The govern­ment has or­dered an in­ves­ti­ga­tion into the im­mu­ni­sa­tion of more than 730,000 chil­dren with the dengue vac­cine that has been sus­pended fol­low­ing an an­nounce­ment by French drug com­pany Sanofi that it could worsen the dis­ease in some cases. While Sanofi’s Dengvaxia is the first ap­proved vac­cine for dengue, sci­en­tists al­ready recog­nised it did not pro­tect equally against the four dif­fer­ent types of the virus. The World Health Or­gan­i­sa­tion (WHO) said it hoped by the end of the year to con­duct a full review of data on the vac­cine. In the mean­time, the WHO rec­om­mended it be used only in peo­ple who had a prior in­fec­tion with dengue.

A new anal­y­sis from six years of clin­i­cal data showed Dengvaxia pro­vides per­sis­tent pro­tec­tive ben­e­fit in those who had prior in­fec­tion. But for those not pre­vi­ously in­fected, more cases of se­vere dis­ease could oc­cur fol­low­ing vac­ci­na­tion. Ac­cord­ing to Sanofi in Manila, 19 li­cences were granted for Dengvaxia, and it was launched in 11 coun­tries, two of which – the Philip­pines and Brazil – had pub­lic vac­ci­na­tion pro­grammes.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.